Paper31258882
Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.
Luinstra M and 9 others. Ther Adv Chronic Dis, 2019. Cited by 24 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. Papers, record 31258882. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31258882
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11,948,753 | Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. | Mov Disord | 2002 | https://conductscience.org/library/papers/11948753 | PubMed |
| 2 | 16,055,882 | Standardisation of spirometry. | Eur Respir J | 2005 | https://conductscience.org/library/papers/16055882 | PubMed |
| 3 | 16,113,455 | The lungs as a portal of entry for systemic drug delivery. | Proc Am Thorac Soc | 2004 | https://conductscience.org/library/papers/16113455 | PubMed |
| 4 | 16,368,444 | A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. | Clin Ther | 2005 | https://conductscience.org/library/papers/16368444 | PubMed |
| 5 | 16,485,914 | Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. | Clin Pharmacokinet | 2006 | https://conductscience.org/library/papers/16485914 | PubMed |
| 6 | 17,630,819 | Medical management of levodopa-associated motor complications in patients with Parkinson's disease. | CNS Drugs | 2007 | https://conductscience.org/library/papers/17630819 | PubMed |
| 7 | 17,956,200 | Apomorphine therapy in Parkinson's disease: a review. | Expert Opin Pharmacother | 2007 | https://conductscience.org/library/papers/17956200 | PubMed |
| 8 | 21,838,677 | Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. | CNS Neurol Disord Drug Targets | 2011 | https://conductscience.org/library/papers/21838677 | PubMed |
| 9 | 22,632,782 | Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. | J Neurol Sci | 2012 | https://conductscience.org/library/papers/22632782 | PubMed |
| 10 | 23,287,001 | Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. | Parkinsonism Relat Disord | 2013 | https://conductscience.org/library/papers/23287001 | PubMed |
| 11 | 23,480,198 | Inhaled biopharmaceutical drug development: nonclinical considerations and case studies. | Inhal Toxicol | 2013 | https://conductscience.org/library/papers/23480198 | PubMed |
| 12 | 23,487,540 | Review: management of Parkinson's disease. | Neuropsychiatr Dis Treat | 2013 | https://conductscience.org/library/papers/23487540 | PubMed |
| 13 | 25,449,210 | Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. | Mov Disord | 2015 | https://conductscience.org/library/papers/25449210 | PubMed |
| 14 | 25,615,881 | The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family. | Eur J Pharm Biopharm | 2015 | https://conductscience.org/library/papers/25615881 | PubMed |
| 15 | 26,173,114 | Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods? | PLoS One | 2015 | https://conductscience.org/library/papers/26173114 | PubMed |
| 16 | 26,453,913 | A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods. | Eur J Pharm Biopharm | 2015 | https://conductscience.org/library/papers/26453913 | PubMed |
| 17 | 26,474,316 | MDS clinical diagnostic criteria for Parkinson's disease. | Mov Disord | 2015 | https://conductscience.org/library/papers/26474316 | PubMed |
| 18 | 26,959,239 | Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. | PLoS One | 2016 | https://conductscience.org/library/papers/26959239 | PubMed |
| 19 | 27,733,560 | Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/27733560 | PubMed |
| 20 | 2,775,615 | The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. | Br J Clin Pharmacol | 1989 | https://conductscience.org/library/papers/2775615 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,646,580 | Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42646580 | PubMed |
| 42,181,371 | Controlled Maxillofacial Administration of Levodopa in a Patient With Parkinson's Disease: A First-in-Human 24-Hour Follow-Up Study. | Cureus | 2026 | https://conductscience.org/library/papers/42181371 | PubMed |
| 42,162,439 | Recent Developments in the Drug Treatment of Parkinson's Disease. | Drugs | 2026 | https://conductscience.org/library/papers/42162439 | PubMed |
| 41,012,486 | An In Vitro-In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41012486 | PubMed |
| 40,775,197 | Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders. | CNS Drugs | 2025 | https://conductscience.org/library/papers/40775197 | PubMed |
| 40,464,628 | The Treatment of Older Patients with Parkinson's Disease. | Dtsch Arztebl Int | 2025 | https://conductscience.org/library/papers/40464628 | PubMed |
| 40,284,461 | Optimization, In Vitro, and In Silico Characterization of Theophylline Inhalable Powder Using Raffinose-Amino Acid Combination as Fine Co-Spray-Dried Carriers. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40284461 | PubMed |
| 39,945,036 | Stabilized Extracellular Vesicle Formulations for Inhalable Dry Powder Development. | Small | 2026 | https://conductscience.org/library/papers/39945036 | PubMed |
| 39,483,816 | Therapeutic effect of an inhaled levodopa dry powder formulation on off episodes in patients with Parkinson's disease. | Ther Adv Neurol Disord | 2024 | https://conductscience.org/library/papers/39483816 | PubMed |
| 38,034,171 | The Administration of Levodopa in a Patient With Parkinson's Disease Using a Novel Maxillofacial Route: A First-in-Human Report. | Cureus | 2023 | https://conductscience.org/library/papers/38034171 | PubMed |
| 37,182,902 | Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease. | J Parkinsons Dis | 2023 | https://conductscience.org/library/papers/37182902 | PubMed |
| 36,559,312 | Development and Pharmacokinetics of a Novel Acetylsalicylic Acid Dry Powder for Pulmonary Administration. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559312 | PubMed |
| 35,775,493 | Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future. | Turk J Pharm Sci | 2022 | https://conductscience.org/library/papers/35775493 | PubMed |
| 35,747,892 | Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. | Neurol Clin Pract | 2022 | https://conductscience.org/library/papers/35747892 | PubMed |
| 35,026,316 | The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders? | Int J Pharm | 2022 | https://conductscience.org/library/papers/35026316 | PubMed |
| 34,575,603 | Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34575603 | PubMed |
| 33,117,256 | Intrinsic Auricular Muscle Zone Stimulation Improves Walking Parameters of Parkinson's Patients Faster Than Levodopa in the Motion Capture Analysis: A Pilot Study. | Front Neurol | 2020 | https://conductscience.org/library/papers/33117256 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| COMT | 1,312 | PubTator's text mining | https://conductscience.org/library/genes/1312 | NCBI Gene |
| MAOB | 4,129 | PubTator's text mining | https://conductscience.org/library/genes/4129 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31258882
GET https://conductscience.org/api/papers/v1/31258882/references?page=2